bd926132-883f-4056-b4a5-7dc0f54f3618
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- GLYCOLYSIS+0.400
- ESTROGEN_RESPONSE_EARLY+0.300
- MYC_TARGETS_V2+0.300
- PEROXISOME+0.300
- XENOBIOTIC_METABOLISM+0.300
- ADIPOGENESIS+0.200
- APICAL_JUNCTION+0.200
- APICAL_SURFACE+0.200
- BILE_ACID_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.300
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- IL6_JAK_STAT3_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- MYC_TARGETS_V1-0.200
- UV_RESPONSE_DN-0.200
- ANDROGEN_RESPONSE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f0f41799-29e8-43f9-b357-722df163e963 | — | — | 0.803 |
| 2 | 59364db9-7bf7-4a15-9798-8e3886078012 | — | — | 0.803 |
| 3 | MNG384 | — | — | 0.774 |
| 4 | SRR8613741 | — | F | 0.764 |
| 5 | MNG965 | — | — | 0.751 |
| 6 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.745 |
| 7 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.743 |
| 8 | SRR8613710 | — | F | 0.742 |
| 9 | MNG754 | — | — | 0.737 |
| 10 | TCGA-OR-A5J3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |